Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-14 4:00 pm Sale |
2023-12-31 | 13G | InflaRx N.V. IFRX |
TANG CAPITAL PARTNERS LP | 1,873,753 3.200% |
-1,126,247 (-37.54%) |
Filing History |
| 2024-02-14 4:00 pm Sale |
2023-12-31 | 13G | Kinnate Biopharma Inc. KNTE |
TANG CAPITAL PARTNERS LP | 2,601,647 5.500% |
-364,068 (-12.28%) |
Filing History |
| 2024-02-14 4:00 pm Sale |
2023-12-31 | 13G | TCR2 Therapeutics Inc. TCRR |
TANG CAPITAL PARTNERS LP | 0 0.000% |
-4,215,864 (Position Closed) |
Filing History |
| 2024-02-14 4:00 pm Unchanged |
2023-12-31 | 13G | Tonix Pharmaceuticals Holding Corp. TNXP |
TANG CAPITAL PARTNERS LP | 0 0.000% |
0 (Unchanged) |
Filing History |
| 2024-02-14 4:00 pm Sale |
2023-12-31 | 13G | Bellerophon Therapeutics, Inc. BLPH |
TANG CAPITAL PARTNERS LP | 0 0.000% |
-1,062,619 (Position Closed) |
Filing History |
| 2024-02-14 4:00 pm Sale |
2023-12-31 | 13G | BioAtla, Inc. BCAB |
TANG CAPITAL PARTNERS LP | 2,524,076 5.300% |
-600,000 (-19.21%) |
Filing History |
| 2024-02-14 4:00 pm Sale |
2023-12-31 | 13G | Bionomics Limited BNOX |
TANG CAPITAL PARTNERS LP | 0 0.000% |
-10,500,000 (Position Closed) |
Filing History |
| 2024-02-14 4:00 pm Purchase |
2023-12-31 | 13G | Bolt Biotherapeutics, Inc. BOLT |
TANG CAPITAL PARTNERS LP | 3,652,244 9.600% |
919,994 (+33.67%) |
Filing History |
| 2024-02-14 4:00 pm Purchase |
2023-12-31 | 13G | CytomX Therapeutics, Inc. CTMX |
TANG CAPITAL PARTNERS LP | 6,550,000 9.800% |
3,039,555 (+86.59%) |
Filing History |
| 2024-02-14 4:00 pm Purchase |
2023-12-31 | 13G | Elevation Oncology, Inc. ELEV |
TANG CAPITAL PARTNERS LP | 4,300,454 9.990% |
2,944,628 (+217.18%) |
Filing History |
| 2024-02-14 4:00 pm Sale |
2023-12-31 | 13G | Genfit S.A. GNFT |
TANG CAPITAL PARTNERS LP | 479,441 1.000% |
-2,163,706 (-81.86%) |
Filing History |
| 2024-02-14 4:00 pm Purchase |
2023-12-31 | 13G | KalVista Pharmaceuticals, Inc. KALV |
TANG CAPITAL PARTNERS LP | 3,440,345 9.960% |
243,899 (+7.63%) |
Filing History |
| 2024-02-14 4:00 pm Sale |
2023-12-31 | 13G | MEI Pharma, Inc. MEIP |
TANG CAPITAL PARTNERS LP | 326,084 4.900% |
-35,000 (-9.69%) |
Filing History |
| 2024-02-14 4:00 pm Sale |
2023-12-31 | 13G | Pyxis Oncology, Inc. PYXS |
TANG CAPITAL PARTNERS LP | 0 0.000% |
-3,470,700 (Position Closed) |
Filing History |
| 2024-02-14 4:00 pm Purchase |
2023-12-31 | 13G | Reviva Pharmaceuticals Holdings, Inc. RVPH |
TANG CAPITAL PARTNERS LP | 3,098,615 9.990% |
832,386 (+36.73%) |
Filing History |
| 2024-02-14 4:00 pm Purchase |
2023-12-31 | 13G | Tarsus Pharmaceuticals, Inc. TARS |
TANG CAPITAL PARTNERS LP | 2,204,797 6.700% |
203,212 (+10.15%) |
Filing History |
| 2024-02-14 4:00 pm Sale |
2023-12-31 | 13G | Tharimmune, Inc. THAR |
TANG CAPITAL PARTNERS LP | 0 0.000% |
-16,837 (Position Closed) |
Filing History |
| 2024-02-05 4:49 pm Purchase |
2024-01-24 | 13G | Precision BioSciences, Inc. DTIL |
TANG CAPITAL PARTNERS LP | 213,333 5.200% |
213,333 (New Position) |
Filing History |
| 2024-02-05 4:48 pm Purchase |
2024-01-24 | 13G | Graphite Bio, Inc. GRPH |
TANG CAPITAL PARTNERS LP | 445,406 5.400% |
445,406 (New Position) |
Filing History |
| 2024-02-02 4:00 pm Sale |
2024-01-26 | 13D | Rain Enhancement Technologies Holdco Inc RAIN |
TANG CAPITAL PARTNERS LP | 0 0.000% |
-4,024,486 (Position Closed) |
Filing History |